# Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT07093554** · PHASE1 · RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 31 (estimated)

## Conditions studied

- Relapse Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Talquetamab
- **DRUG:** Ciltacabtagene Autoleucel

## Key facts

- **NCT ID:** NCT07093554
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-02
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07093554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07093554, "Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07093554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*